Open Access

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

  • Patrizia Mondello1, 2, 3Email author,
  • Vincenzo Pitini1,
  • Valeria Barresi1,
  • Elliott Joseph Brea4, 5,
  • Cristian Di Mirto1,
  • Carmela Arrigo6,
  • Salvatore Cuzzocrea2 and
  • Michael Mian7, 8
Experimental Hematology & Oncology20165:1

DOI: 10.1186/s40164-015-0030-1

Received: 29 October 2015

Accepted: 29 December 2015

Published: 6 January 2016

Abstract

Background

Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy (MG) is a known adverse prognostic factor for DLBCL. Because this subset of patients does not benefit from R-CHOP, new therapeutic options are required. Herein, we report the first case of extranodal DBCL of the lung with a concomitant MG who achieved a long lasting complete remission with lenalidomide.

Case presentation

The 73-year-old male patient presented with lateral cervical lymphadenopathy, B symptoms, lactate dehydrogenase and beta2-microglobulin elevation. Computed tomography (CT) showed mediastinal lymphadenopathy and bilateral lung involvement. Biopsy of both disease locations revealed the presence of DLBCL. Successive bone marrow trephine biopsy proved the presence of concordant DLBCL involvement. At the time of diagnosis, a MG was present as well. The patient did not respond to the standard treatments, and subsequently underwent lenalidomide 25 mg/m2 days 1–21 q28 plus dexamethasone 40 mg days 1–4, 9–12 e 17–20. This therapeutic regimen was efficacious and safe as salvage therapy in extranodal DBCL with a MG. Furthermore, we observed a close association between DLBCL response to therapy and MG levels, suggesting that the amount of M-protein might be a surrogate marker of disease response.

Conclusion

Although DLBCL associated with MG does not respond properly to the standard treatments, it is highly sensitive to lenalidomide, which is why we endorse its role as treatment of choice in this subset of patients. In addition, MG levels appear to correlate with tumor burden, suggesting that it might be a useful marker of disease response. Prospective trials to validate these observations are warranted.

Keywords

Diffuse large B-cell lymphoma Monoclonal gammopathy Serum free light chain Lenalidomide

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL), accounting for about 30 % of all new diagnoses [1]. Despite its typical morphology, it is a very heterogeneous disease consisting of many subtypes. Gene expression profiling (GEP) studies have identified three main DLBCL subgroups based on the cell of origin: germinal center B-cell (GCB), activated B-cell (ABC) and unclassified DLBCL being mostly represented by primary mediastinal B-cell lymphoma (PMBCL) [2, 3]. These three subtypes have distinct oncogenic driver pathways resulting in a different prognosis [4, 5]. In particular, ABC DLBCL patients have shown a worse survival than GCB DLBCL when treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP) [6]. Another clinical parameter reflecting the heterogeneity of this disease is the presence of monoclonal gammopathy (MG) in some patients [7]. DLBCL with MG often shows an immunoblastic differentiation, however, due to its morphologic resemblance with plamosmobastic lymphoma (PBL), diagnosis can be controversial. Nevertheless, the immunophenotype of these diseases is different: DLBCL with MG usually express the pan-B-cell antigens [8] while PBL has a characteristic immunophenotypic pattern with cluster of differentiation (CD) 20 and CD 79a negativity in combination with markers of post germinal center B-cell and plasma cell, such as MUM1+, IgG+, CD 138+, CD 38+ [9, 10]. Furthermore, most of PBL develop in the setting of viral infection and/or immunodeficiency. In addition, a rare variant of PBL is characterized by having a translocation of ALK to the clathrin gene on chromosome 17 [11]. Even multiple myeloma (MM) with plasmobastic features present morphological similarities to DLBCL with MG. However, its immunophenotype resembles PBL [1214]. Moreover, DLBCL with MG differ from MM with plasmobastic features by the absence of bone involvement with radiographically evident lytic lesions [15].

Usually, patients affected by DLBCL with MG present with advanced stage disease, involvement of extranodal sites and high IPI-score [16]. Clinical data suggest that DLBCL with MG has a very aggressive clinical course, not adequately responding to standard treatments, which is why alternative approaches are needed. Lenalidomide, an oral immunomodulatory drug (IMiDs) with multiple mechanisms of action, including direct antitumor and immunomodulatory effects [17], has demonstrated to be active as single agent in NHL [18] with a higher response rate in non-GCB with respect to GCB patients (55 vs 9 %, respectively) [19]. Nevertheless, lenalidomide represents the cornerstone of MM management, providing rapid and sustained disease control in relapsed/refractory [20, 21] as well as in newly diagnosed patients [22]. Based on its dual efficacy on lymphoma and on myeloma cells, lenalidomide might have a significant role in DLBCL with MG.

Herein, we present the first case of extranodal DBCL of the lung associated with a MG resistant to standard therapies but highly responsive to lenalidomide. Furthermore, we observed a close association between DLBCL response to therapy and MG serum levels, suggesting that in this specific situation the dosage of the MG might be a valid marker of disease response.

Case presentation

In August 2011, a 73 year-old man presented with lateral cervical lymphadenopathy, B symptoms and lactate dehydrogenase (LDH) and beta2-microglobulin (B2 M) elevation (890 U/L, upper normal 460 and 3176 ng/mL, upper normal 2150, respectively). Computed tomography (CT) revealed mediastinal lymphadenopathy and bilateral lung involvement. Histological examination of a lymph node and lung biopsies detected the presence of a DLBCL with an intermediate-high proliferation index (55 % Ki-67 positive cells) without plasmoblastic differentiation. In immunohistochemistry, the neoplastic tissue was CD 20+, CD 19+, CD 79 alfa+, CD 10+, CD 3−, CD 5−, CD 23+, CD 38−, CD138−, BCL2−, BCL6+, MUM1+, suggesting a non-GCB origin [23], and suggestive for IgG expression (Fig. 1). Bone marrow trephine biopsy proved the presence of concordant DLBCL involvement. The IPI score was high due to four risk factors (stage IV, age >60, elevated LDH and >1 extranodal site). At the time of diagnosis, a monoclonal gammopathy was accidentally discovered. The M-gradient was of immunoglobulin (Ig) G k-type, with a serum concentration of 22.5 g/dL. Serum λ free light chains (FLC), the same subtype as expressed by the neoplastic cells, were elevated (410.3 mg/l; range 5.5–355.2) resulting in an abnormal κ/λ FLC ratio. All the other Ig levels were normal (IgA 3.32—normal range 0.82–4.76 g/dL, IgM 1.84—normal range 0.30–2.27). The Bence-Jones proteinuria was absent. The concomitant presence of a multiple myeloma was excluded since the bone marrow plasmacytosis was less than 5 % and the patient had no end-organ damage according to the CRAB criteria [24]. Since the patient was in a good clinical condition (performance status of 1), he underwent R-CHOP. Due to stable disease assessed by CT scan after the fourth cycle treatment was discontinued. At this time the MG remained stable (Fig. 2). Six months later the patient suffered a histological-proven progression in the lung. Due to a poor performance status (PS 2) at the time of relapse and his ineligibility to ASCT, the patient underwent bendamustine 100 mg/m2 days 1–2 q28 plus rituximab 375 mg/m2 every 28 days for four cycles. Disease restaging after treatment completion revealed progressive disease (PD) (Fig. 3) as well as an increase of the MG (Fig. 2). Due to the lack of other treatment options, he finally underwent lenalidomide 25 mg/m2 days 1–21 q28 thereafter. Dexamethasone 40 mg days 1–4, 9–12 e 17–20 for the first four cycles and only days 1–4 was added as well. This because dexamethasone has demonstrated activity as single agent in reducing paraproteinemia and improving quality of life [25, 26]. Moreover, it synergistically inhibits tumor growth and induces apoptosis when combined with lenalidomine [27].
Fig. 1

Diffuse large B-cell lymphoma (DLBCL) in lymph node biopsy. Immunohistochemistry revealed IgG staining in the cytoplasm of some neoplastic cells (IgG stain; original magnification, ×200). Absence of CD38 expression in neoplastic cells and a positive staining in intermingled plasma cells (original magnification, ×400). Absence of CD138 stain in neoplastic cells (original magnification, ×400)

Fig. 2

Trend of γ-globulin dosage during the disease course

Fig. 3

Computed tomography (CT) of the torax. a Pathological tissue with elongated morphology of maximum diameter of 6 cm. b Almost complete disappearance of the pathological mass previously observed

Hematologic toxicity was limited to reversible grade two neutropenia and thrombocytopenia after the sixth cycle. Except for fatigue grade two, no extra-hematologic toxicities were observed. Two months after treatment start, the patient’s general conditions improved and after 5 months he achieved a complete remission (CR) (Fig. 3). For the first time paraprotein was no longer detectable and immunofixation (IF) was negative as well (Fig. 2). Overall, the patient underwent 15 cycles of lenalidomide until he suffered relapse leading to death. Interestingly, the reappearance of a monoclonal IgG and of FLC k/l abnormal ratio preceded relapse (Fig. 2).

Herein, we report the case of a patient with DLBCL of the lung associated with the presence of a sieric MG of IgG λ type. Despite the histologic morphology not being compatible with a plasmablastic differentiation, the levels of MG following lymphoma response and the absence of multiple myeloma features suggest that the paraprotein was produced by the lymphoma cells. Moreover, neoplastic cells represented with a λ light chain restriction the same subtype of light chain as the aberrant MG. As previously reported by others, MG was associated with a non-GCB subtype [28]. This could probably be explained by the fact that ABC DLBCL develops from post-germinal center B-cells and is associated with an up-regulation of Blimp-1, which is a master regulator of plasma cell differentiation [29]. Consistent with previous reports [9, 28], the presence of MG was associated with advanced stage, involvement of extranodal sites, elevated LDH and high IPI score. Despite this usually unfavorable risk profile at diagnosis, data regarding the outcome of such patients are still conflicting. Maurer et al. [30] showed that a monoclonal elevation of FLC ratio was only moderately associated with DLBCL outcome, while more recent analyses have observed a poor outcome in DLBCL with paraproteinemia [28, 31], especially in the ABC subtype [7].

As also observed by others, the benefit from R-CHOP in patients with DLBCL with a serum MG is very limited [7, 16] and new therapeutic options are required. Lenalidomide has demonstrated to be highly active in non-GCB [29] as well as in MM [22]. Recent insights into the biology of IMiDs have identified cereblon, a substrate-recognition component of an ubiquitin ligase [32], as a crucial molecule for the immunomodulatory and antiproliferative activities of lenalidomide [33, 34]. Lenalidomide-bound cereblon acquires the ability to target the proteosomal degradation of two B-cell transcription factors, IKZF1 and IKZF3, an essential step in the anti-myeloma effect [35]. In addition, lenalidomide induces the cereblon-mediated down-regulation of IFR4 leading to inhibition of the B-cell receptor-NF-kB signaling pathway [34], which is aberrant in ABC DLBCL [2]. Despite breakthrough studies that identified cereblon as a critical lenalidomide target [32, 33], there are challenges in its use as a biomarker. In particular, no correlation between cereblon gene expression or protein level to sensitivity or to intrinsic resistance to lenalidomide treatment has been observed [36, 37]. Therefore, the clinical value of cereblon expression as a predictive or prognostic biomarker is still questionable.

In our case, despite inefficacy of R-CHOP and R-bendamustine, lenalidomide induced a complete response with the disappearance of paraproteinemia. This striking efficacy might be related to its dual activity on lymphoma and on plasma cells, allowing to overcome the adverse effect connected to ABC DLBC and MG. Moreover, the favorable toxicity profile of lenalidomide translates into a high feasibility since ABC DLBC with MG are more common among old age patients [7]. Interestingly, we observed a direct correlation between DLBCL response to treatment and MG serum levels, suggesting that the aberrant proteins were produced by the neoplastic cells. Consequently, the monoclonal component might be used as a marker of disease in such cases.

Conclusions

In conclusion, these data suggest that DLBCL associated with monoclonal gammopathy does not respond properly to the standard treatments while it could be highly sensitive to lenalidomide. The IMID was able to overcome the negative impact of MG and ABC DLBCL on response, which is why lenalidomide might be the treatment of choice for this subset of patients. In addition, MG levels appear to correlate with tumor burden, suggesting that it might be a useful marker of disease response. Prospective trials to validate these observations are warranted.

Consent

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Abbreviations

DLBCL: 

diffuse large B cell lymphoma

NHL: 

B-cell non-Hodgkin lymphoma

GCB: 

germinal center B-cell

ABC: 

activated B-cell

PMBCL: 

primary mediastinal B-cell lymphoma

R-CHOP: 

rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone

MG: 

monoclonal gammopathy

IMiDs: 

immunomodulatory drug

MM: 

multiple myeloma

LDH: 

lactate dehydrogenase

B2M: 

beta2-microglobulin

CD: 

cluster of differentiation

Ig: 

immunoglobulin

FLC: 

free light chains

PD: 

progressive disease

CR: 

complete remission

IF: 

immunofixation

Declarations

Authors’ contributions

MP collected the data, revised the literature and wrote the manuscript; SC and MM were involved in revising the manuscript critically for important intellectual content; VB, CA, EB, CDM and VP participated in the acquisition of data and in the manuscript layout; SC participated in the coordination of the study and gave final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements

This article did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Human Pathology, University of Messina
(2)
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina
(3)
Lymphoma Department, Lymphoma Service, Memorial Sloan Kettering Cancer Center
(4)
Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute
(5)
Weill Cornell Medical College
(6)
Department of Internal Medicine, University of Messina
(7)
Department of Hematology and CBMT, Ospedale di Bolzano
(8)
Universitätsklinik für Innere Medizin V, Hämatologie and Onkologie

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.View ArticlePubMedGoogle Scholar
  2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.View ArticlePubMedGoogle Scholar
  3. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105:13520–5.View ArticlePubMed CentralPubMedGoogle Scholar
  4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.View ArticlePubMedGoogle Scholar
  5. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–6.View ArticlePubMed CentralPubMedGoogle Scholar
  6. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23.View ArticlePubMedGoogle Scholar
  7. Kim YR, Kim SJ, Cheong JW, Kim Y, Jang JE, Lee JY, et al. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Ann Hematol. 2014;93:1867–77.View ArticlePubMedGoogle Scholar
  8. de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology. 2003;43:509–28.View ArticlePubMedGoogle Scholar
  9. Gaidano G, Cerri M, Capello D, Berra E, Deambrogi C, Rossi D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002;119:622–8.View ArticlePubMedGoogle Scholar
  10. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806–15.View ArticlePubMedGoogle Scholar
  11. De Paepe P, Baens M, Van Krieken H, Verhasselt B, Stul M, Simons A, et al. ALK activation by the CTLC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood. 2003;102:2638–41.View ArticlePubMedGoogle Scholar
  12. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413–20.PubMedGoogle Scholar
  13. Carbone A, Gaidano G, Gloghini A, Ferlito A, Rinaldo A, Stein H. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol. 1999;108:95–9.View ArticlePubMedGoogle Scholar
  14. Stewart JM, Krishnamurthy S. Fine-needle aspiration cytology of a case of HIV-associated anaplastic myeloma. Diagn Cytopathol. 2002;27:218–22.View ArticlePubMedGoogle Scholar
  15. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–7.PubMedGoogle Scholar
  16. Cox MC, Di Napoli A, Scarpino S, Salerno G, Tatarelli C, Talerico C, Lombardi M, et al. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One. 2014;9:e93903.View ArticlePubMed CentralPubMedGoogle Scholar
  17. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849–58.View ArticlePubMedGoogle Scholar
  18. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.View ArticlePubMedGoogle Scholar
  19. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–66.View ArticlePubMedGoogle Scholar
  20. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.View ArticlePubMedGoogle Scholar
  21. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.View ArticlePubMedGoogle Scholar
  22. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.View ArticlePubMedGoogle Scholar
  23. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.View ArticlePubMedGoogle Scholar
  24. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.View ArticlePubMedGoogle Scholar
  25. Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol. 1991;36(3):171–5.View ArticlePubMedGoogle Scholar
  26. Newcom SR. Case reports: continuous corticosteroids for refractory poorly differentiated lymphocytic lymphoma. Am J Med Sci. 1996;312(3):136–7.View ArticlePubMedGoogle Scholar
  27. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011;35(3):380–6.View ArticlePubMedGoogle Scholar
  28. Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, et al. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am J Hematol. 2004;89:417–22.View ArticleGoogle Scholar
  29. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.View ArticlePubMedGoogle Scholar
  30. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;29:1620–6.View ArticlePubMed CentralPubMedGoogle Scholar
  31. Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Briere J, Petrella T, et al. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lym- phoma. Leuk Lymphoma. 2013;54:1898–907.View ArticlePubMedGoogle Scholar
  32. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.View ArticlePubMedGoogle Scholar
  33. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–35.View ArticlePubMed CentralPubMedGoogle Scholar
  34. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502.View ArticlePubMedGoogle Scholar
  35. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–9.View ArticlePubMed CentralPubMedGoogle Scholar
  36. Klimowicz A, Neri P, Belch A, Belch A, Dean M, Ren L, et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood. 2012;120:931.Google Scholar
  37. Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use ofstandardized reagents and understanding of gene complexity. Br J Haematol. 2014;164:233–44.View ArticlePubMed CentralPubMedGoogle Scholar

Copyright

© Mondello et al. 2016

Advertisement